Webb spots outsized early black hole & GSK hepatitis B drug boosts cures - News (May 29, 2026)

First human cell reprogramming trial & AI tumor typing from slides - News (Jun 11, 2026)

Please support this podcast by checking out our sponsors: - Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad [https://try.lindy.ai/tad] - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad [https://try.krispcall.com/tad] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: FIRST HUMAN CELL REPROGRAMMING TRIAL - LIFE BIOSCIENCES HAS DOSED THE FIRST PERSON IN A PARTIAL CELLULAR REPROGRAMMING GENE-THERAPY TRIAL FOR GLAUCOMA, A MILESTONE FOR ANTI-AGING MEDICINE WHERE SAFETY AND CANCER RISK ARE KEY CONCERNS. AI TUMOR TYPING FROM SLIDES - THE HETAIROS AI SYSTEM PREDICTS WHO-ALIGNED BRAIN AND SPINAL CORD TUMOR SUBTYPES FROM ROUTINE PATHOLOGY SLIDES, POTENTIALLY SPEEDING DIAGNOSIS AND GUIDING WHICH MOLECULAR TESTS TO RUN WHEN ACCESS IS LIMITED. AI-DESIGNED UNIVERSAL CORONAVIRUS VACCINE - CAMBRIDGE RESEARCHERS REPORT THE FIRST HUMAN TEST OF AN AI-DESIGNED VACCINE COMPONENT AIMING FOR A UNIVERSAL CORONAVIRUS SHOT, GENERATING CROSS-SARBECOVIRUS ANTIBODIES BUT WITH MODEST EARLY RESPONSES. CANADA’S UNDER-16 SOCIAL MEDIA BILL - CANADA’S PROPOSED SAFE SOCIAL MEDIA ACT WOULD RESTRICT SOCIAL MEDIA ACCESS FOR UNDER-16S AND REGULATE AI CHATBOTS, SPARKING DEBATE OVER CHILD SAFETY, PLATFORM COMPLIANCE EXEMPTIONS, AND FREE-SPEECH RISKS. CHINA AND NORTH KOREA RESET - XI JINPING’S RARE VISIT TO NORTH KOREA REAFFIRMED TIES WITH KIM JONG UN WHILE SIDESTEPPING DENUCLEARIZATION, SIGNALING SHIFTING REGIONAL PRIORITIES AND LIKELY KNOCK-ON EFFECTS FOR U.S., JAPAN, AND SOUTH KOREA COORDINATION. CHINA EV EXPORTS AND BYD - CHINA’S PASSENGER CAR EXPORTS JUMPED AS EV AND PLUG-IN HYBRID SHIPMENTS SURGED; BYD IS PUSHING FOR GLOBAL DOMINANCE WITH EUROPE INVESTMENT AND LOCAL ASSEMBLY PLANS AMID RISING TARIFFS AND SCRUTINY. UKRAINE’S PLAN FOR DRONE SCALE - UKRAINE SAYS IT COULD PRODUCE UP TO 20 MILLION MILITARY DRONES ANNUALLY WITH NATO FUNDING, HIGHLIGHTING DRONES AS A DECISIVE CAPABILITY WHILE RAISING QUESTIONS ABOUT SUPPLY CHAINS, SENSORS, AND ALLIED COMMITMENTS. ARCTIC ICEBERGS RESHAPING DEEP SEA - A NATURE STUDY LINKS RISING FRAM STRAIT ICEBERG TRAFFIC TO GREENLAND AND RUSSIAN ARCTIC GLACIER CHANGES, SHOWING CLIMATE-DRIVEN IMPACTS THAT EXTEND TO DEEP-OCEAN HABITATS AND ARCTIC SHIPPING HAZARDS. NEW TECH POWER PLAYERS DEBATE - A MARKET NARRATIVE IS FORMING AROUND AI AND SPACE COMPANIES LEADING THE NEXT ERA OF PUBLIC MARKETS, WITH TALK OF A POST-FAANG WORLD SHAPED BY POTENTIAL IPOS LIKE SPACEX, OPENAI, AND ANTHROPIC. Episode Transcript First human cell reprogramming trial In health and biotech, a major first: Life Biosciences says it has dosed the first participant in a clinical trial using “partial cellular reprogramming,” a gene-therapy strategy meant to make older cells behave more like younger ones. The first target is glaucoma, aiming to help damaged optic-nerve neurons recover. This is a turning point because the field is moving from compelling animal results into human safety testing—and safety is the headline. One fear is that pushing cells back toward a more youthful state could also nudge them toward uncontrolled growth. The eye is considered a cautious place to start, because side effects are more likely to stay localized. If it looks safe and shows even early hints of nerve function returning, it could open doors well beyond glaucoma. AI tumor typing from slides Also in medicine, researchers in Heidelberg unveiled an AI system called Hetairos that can predict the molecular subtype of brain and spinal cord tumors using routine microscope tissue sections—potentially avoiding the long wait for specialized molecular tests. Why it matters: for many central nervous system cancers, the exact molecular category determines diagnosis and treatment options, but advanced profiling can take around two weeks and isn’t available everywhere. Hetairos was trained across a large international dataset and, in confident cases, delivered high accuracy in minutes. The developers are careful to frame it as a tool to support pathologists—not replace molecular workups—but it could be a big win for speed, especially when tumor samples are small or resources are constrained. AI-designed universal coronavirus vaccine Another notable step for AI in healthcare: University of Cambridge researchers say they’ve tested in humans, for the first time, a vaccine whose core component was designed entirely by artificial intelligence. The goal is a broader “universal” coronavirus vaccine—something that could protect not only against today’s COVID-19 variants, but also related bat viruses that could jump to people in a future outbreak. Early results reportedly show the vaccine was safe and produced antibodies that recognize multiple related viruses, though the immune response was described as modest and durability is still an open question. The bigger story is the approach: using AI to rapidly identify stable viral targets that don’t change much, potentially speeding the path to vaccines that hold up better as viruses evolve. Canada’s under-16 social media bill In Canada, the government has introduced a proposed Safe Social Media Act that would restrict access to social media for anyone under 16—similar in spirit to Australia’s teen social media ban, but with a twist. Canada’s plan includes an exemption: platforms could avoid the ban if they can demonstrate strong policies that reduce harm to minors. Supporters argue that creates leverage to force better safety practices; critics worry it becomes a loophole, and that the law’s definitions of harmful content could expand into broader censorship. The proposal also ropes in AI chatbots, reflecting growing anxiety about how conversational AI can influence vulnerable users. Expect this debate to intensify as leaders discuss AI and child safety at the upcoming G7. China and North Korea reset On geopolitics, China’s President Xi Jinping has visited North Korea for the first time in nearly seven years, publicly reaffirming ties with Kim Jong Un—while pointedly avoiding any mention of denuclearization. That omission is drawing attention because it comes soon after Xi met President Trump in Beijing, where Washington described a shared goal of a denuclearized North Korea—language Beijing didn’t echo publicly. Meanwhile, Pyongyang is leaning hard into the idea that its nuclear status is permanent, highlighting new facilities and rapid arsenal growth. Analysts read Xi’s silence as a signal that China may be prioritizing strategic alignment over pressure on North Korea, a shift that could push tighter U.S. security coordination with South Korea and Japan. China EV exports and BYD Staying with China, the country’s auto story is increasingly an export story. New data show China’s passenger car exports surged in May, with electric and plug-in hybrid shipments making up more than half of the total. One driver: higher gasoline and diesel prices linked to the war in Iran, which are making EVs look more attractive abroad. At home, China’s car market is cooling, and competition is squeezing margins—so companies are chasing growth overseas. BYD, now the world’s largest EV seller, says it wants to become the biggest automaker on the planet within five years. It’s talking up European investment and local assembly to navigate tariffs, but that expansion is coming with scrutiny too, including regulatory and labor questions around new facilities, and added geopolitical pressure after the Pentagon labeled BYD a “Chinese military company.” Ukraine’s plan for drone scale From the front lines of modern warfare, Ukraine’s defense ministry says it could scale to produce around 20 million military drones a year—possibly more—if NATO allies provide enough funding and investment in Ukrainian production lines. This is eye-popping because drones have become central to Ukraine’s battlefield effectiveness, from reconnaissance to long-range strikes, and Kyiv is pitching partners on a massive industrial ramp-up with combat testing and shared data as part of the deal. The hurdles are just as real: supply chains for chips, sensors, and other components could become bottlenecks, and it’s unclear whether allies will commit at the level Ukraine is seeking. Still, the message is clear: drones aren’t a side capability anymore—they’re a core pillar of military power. Arctic icebergs reshaping deep sea In climate and oceans, a Nature study reports a sharp rise in Arctic iceberg numbers passing through the Fram Strait since the early 2000s. The drivers include faster calving from destabilized glaciers in northeast Greenland and parts of the Russian Arctic, plus retreating sea ice that lets icebergs move more freely. What’s especially interesting is the downstream effect: researchers observed debris-rich icebergs dropping rocks onto the deep seafloor—creating patches of hard surface where there used to be mostly soft sediment. That “stone rain” can change what lives down there, helping sponges and anemones colonize new areas and gradually reshaping deep-ocean ecosystems. It also increases practical risks, from Arctic shipping hazards to offshore operations as activity moves north. New tech power players debate And finally, a note on markets and tech culture: there’s growing chatter that the old “FAANG” shorthand for tech dominance is being overtaken by a new lineup centered on AI and space. One proposed replacement acronym floating around is “MANGOS,” pointing to companies like Meta, Nvidia, Google, and potential public-market giants such as OpenAI, Anthropic, and SpaceX. This is less about the acronym itself and more about what it reflects: investor attention is shifting toward companies building the AI platforms, models, and computing muscle that shape the next decade. It’s also a reminder that an AI-led economy could rearrange jobs and business models quickly—creating winners, displacing others, and leaving regulators scrambling to keep up. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Gene therapy to rejuvenate cells & Twice-yearly HIV prevention rollout - News (Jun 10, 2026)

Please support this podcast by checking out our sponsors: - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad [https://try.lindy.ai/tad] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: GENE THERAPY TO REJUVENATE CELLS - A FIRST-IN-HUMAN TRIAL IS TESTING PARTIAL CELLULAR REPROGRAMMING VIA GENE THERAPY TO HELP GLAUCOMA-DAMAGED OPTIC NERVES, WITH SAFETY AND CANCER RISK THE MAIN WATCHPOINTS. TWICE-YEARLY HIV PREVENTION ROLLOUT - SOUTH AFRICA IS ROLLING OUT LENACAPAVIR, A TWICE-YEARLY INJECTABLE HIV PREP OPTION, AIMING TO IMPROVE ADHERENCE WHILE ADVOCATES WARN SUPPLY AND CLINIC ACCESS REMAIN MAJOR HURDLES. AI-DESIGNED VACCINE ENTERS HUMAN TRIALS - CAMBRIDGE RESEARCHERS REPORTED EARLY HUMAN RESULTS FOR AN AI-DESIGNED SARBECOVIRUS VACCINE, A STEP TOWARD BROADER CORONAVIRUS PROTECTION BEYOND SARS-COV-2 VARIANTS. GLP-1 DRUGS AND CANCER SIGNALS - NEW ONCOLOGY MEETING ANALYSES LINK GLP-1 MEDICINES LIKE SEMAGLUTIDE AND TIRZEPATIDE TO LOWER CANCER RISK SIGNALS, THOUGH RESEARCHERS STRESS THE DATA IS CORRELATIONAL, NOT PROOF. OPENAI MOVES TOWARD IPO - OPENAI HAS CONFIDENTIALLY FILED FOR AN IPO, SPOTLIGHTING THE AI BOOM’S INVESTOR APPETITE WHILE RAISING QUESTIONS ABOUT PROFITABILITY AND THE SOARING COST OF DATA-CENTER INFRASTRUCTURE. XI VISITS NORTH KOREA AGAIN - XI JINPING’S FIRST NORTH KOREA VISIT IN YEARS REAFFIRMED TIES WITH KIM JONG UN WHILE SIDESTEPPING DENUCLEARIZATION, SHIFTING REGIONAL CALCULATIONS FOR THE U.S., SOUTH KOREA, AND JAPAN. EUROPE PUSHES UKRAINE PEACE TALKS - GERMANY SAYS EUROPE IS PREPARED TO LEAD A UKRAINE-RUSSIA NEGOTIATING PUSH, COORDINATING WITH THE U.S. BUT SIGNALING A MORE ASSERTIVE EUROPEAN ROLE AND TOUGHER CONDITIONS. CHINA CAR EXPORTS RESHAPE MARKETS - CHINA’S PASSENGER-CAR EXPORTS JUMPED, LED BY EVS AND PLUG-IN HYBRIDS, AS DOMESTIC DEMAND WEAKENS—INTENSIFYING GLOBAL COMPETITION AND PRICING PRESSURE FOR LEGACY AUTOMAKERS. Episode Transcript Gene therapy to rejuvenate cells We start in health and biotech, with a milestone that sounds like science fiction but is now officially in human testing. Life Biosciences says it has dosed the first participant in a clinical trial of “partial cellular reprogramming,” a gene-therapy strategy designed to coax aging cells into behaving more youthfully. The first target is glaucoma, aiming to regenerate or restore optic-nerve neurons that have been damaged. What makes this especially significant is that the field is moving from encouraging animal results into the messy reality of human safety testing. And safety is the headline: researchers worry that pushing cells toward a more youthful, flexible state could also nudge them toward uncontrolled growth. That’s why the eye is seen as a cautious starting point—any side effects are more likely to be contained and monitored closely. Twice-yearly HIV prevention rollout Still in public health, South Africa is beginning a rollout of lenacapavir, a twice-yearly injectable drug used to prevent HIV infection. The promise here is straightforward: if prevention doesn’t rely on remembering a pill every day, more people can stay protected. Clinical trial results in the region have been striking, including a Johannesburg study that reported full protection over a six-month window. But the rollout is also exposing familiar problems—scale and access. The country has secured enough doses, for now, to cover hundreds of thousands of people for a year, with initial distribution focused on higher-risk groups and provinces with heavy HIV burden. Advocates argue that’s nowhere near enough for population-level impact, and they’re also worried about how people will be reached after U.S. aid cuts shuttered specialized clinics many relied on. The government says staff training and service adjustments are underway, but concerns about stigma and confidentiality in mainstream facilities remain front and center. AI-designed vaccine enters human trials Next, a different kind of pandemic preparedness: researchers at the University of Cambridge report the first human test of a vaccine whose key component was designed entirely by artificial intelligence. The goal isn’t just another update for COVID—it’s broader protection across the sarbecovirus family, which includes SARS-CoV-1, SARS-CoV-2, and related animal coronaviruses that could spill over in the future. Early phase-one results suggest the vaccine was safe and triggered antibodies that recognize multiple related viruses. The catch is that the immune response looked modest, and the big unanswered questions are durability and real-world protection. Even so, the significance is hard to miss: it’s a credible step toward vaccines that are built to anticipate viral evolution, not just chase it. GLP-1 drugs and cancer signals And from prevention to treatment signals: new analyses presented at the American Society of Clinical Oncology are fueling interest in whether GLP-1 drugs—best known for diabetes and weight loss—might also be linked to lower cancer risk or slower progression. Several studies using medical databases found associations that look encouraging, including reported reductions in risks for certain cancers like breast, colorectal, liver, and non-small cell lung cancer. One analysis even suggested a breast cancer reduction that may be larger than weight loss alone would explain. Researchers are careful to underline what this is and isn’t: it’s not proof that GLP-1 medicines prevent cancer, because retrospective data can’t fully untangle lifestyle changes or other health differences. What it does do is sharpen the case for more targeted trials that track biology—like inflammation, metabolism, and immune markers—to see if there’s a real protective effect. OpenAI moves toward IPO Turning to tech and markets, OpenAI has reportedly confidentially filed for an initial public offering. That doesn’t mean an IPO is imminent, but it’s a serious signal that one of the most closely watched AI companies is keeping the door open for a major Wall Street debut. The backdrop is a broader investor hunger for AI exposure, with other big names also rumored to be lining up. The tension here is that scale doesn’t automatically mean profit: OpenAI’s products have ballooned in reach—ChatGPT is said to be nearing about 900 million monthly users—but the cost of building and renting the computing power behind modern AI remains enormous. If OpenAI and peers do head to public markets, investors will be betting not just on adoption, but on whether these companies can control infrastructure costs and navigate community and regulatory pushback around data-center expansion. Xi visits North Korea again Now to geopolitics in East Asia: China’s President Xi Jinping has visited North Korea for the first time in nearly seven years, publicly reaffirming ties with Kim Jong Un—while notably avoiding any mention of denuclearization. The timing is delicate. Xi’s trip comes soon after a meeting with President Trump in Beijing, where the White House said both sides shared the goal of a denuclearized North Korea, a framing Beijing did not echo publicly. Analysts see Xi’s silence as meaningful, especially as Pyongyang presents its nuclear status as permanent and showcases new nuclear infrastructure. The broader implication is regional: if China appears more willing to live with a nuclear-armed North Korea, Washington, Seoul, and Tokyo could tighten security coordination further—deepening the very alignment Beijing has been criticizing. Europe pushes Ukraine peace talks On the war in Ukraine, Germany says European leaders are ready to take a leading role in negotiations to end Russia’s full-scale invasion, while staying closely coordinated with the United States. This follows a London meeting involving Ukraine, France, Germany, and the U.K., and comes as U.S.-led mediation since early 2025 has delivered limited breakthroughs—while Washington’s bandwidth is increasingly stretched by the U.S.-Israeli war with Iran. European leaders are pushing for direct Ukraine–Russia talks with active U.S. and European participation, and they’ve emphasized conditions like an immediate ceasefire, negotiations starting from current lines, and security guarantees for Ukraine, alongside keeping Russian assets frozen until compensation is addressed. The big unknown is whether Vladimir Putin engages at all—and Berlin is openly warning this could take time. China car exports reshape markets Finally, the global auto race is tilting faster toward China. New industry data shows China’s passenger-car exports surged in May, with electrified vehicles—pure EVs and plug-in hybrids—making up a growing share. Part of the immediate context is energy price volatility tied to the Iran war, which has pushed up gasoline and diesel prices and made electric options more appealing in some markets. But the longer story is structural: China’s domestic car sales have been weakening for months, so automakers are leaning harder on overseas demand. BYD, in particular, is accelerating its international push and says it wants to become the world’s largest automaker within five years. It’s also investing in Europe, planning local assembly in Hungary, and trying to sidestep tariff pressure by producing inside the EU—though the company is also facing scrutiny over local compliance issues and added geopolitical pressure after being placed on a U.S. Pentagon list tied to Chinese military-linked firms. For consumers, more Chinese exports can mean lower prices and faster EV adoption. For established automakers, it’s a direct challenge to market share and margins. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

China’s brain implant milestone & South Africa’s twice-yearly HIV prevention - News (Jun 9, 2026)

Please support this podcast by checking out our sponsors: - KrispCall: Agentic Cloud Telephony - https://try.krispcall.com/tad [https://try.krispcall.com/tad] - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily [https://get.consensus.app/automated_daily] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: CHINA’S BRAIN IMPLANT MILESTONE - CHINA APPROVED THE NEO BRAIN-COMPUTER INTERFACE IMPLANT FOR COMMERCIAL SALE, A STEP BEYOND NEURALINK’S LIMITED TRIALS. KEYWORDS: BRAIN CHIP, BCI, PARALYSIS, APPROVAL, NEURAL DATA PRIVACY. SOUTH AFRICA’S TWICE-YEARLY HIV PREVENTION - SOUTH AFRICA BEGAN ROLLING OUT LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION INJECTION, AIMING TO SOLVE DAILY-PILL ADHERENCE PROBLEMS. KEYWORDS: HIV, PREP, LENACAPAVIR, GLOBAL FUND, ACCESS GAP. GLP-1 DRUGS: BENEFITS AND RISKS - GLP-1 MEDICATIONS CONTINUE SPREADING BEYOND DIABETES INTO WEIGHT LOSS, WITH REPORTS OF IMPROVED MOBILITY BUT ALSO NAUSEA AND EMOTIONAL “FLATNESS” FOR SOME. KEYWORDS: GLP-1, SEMAGLUTIDE, TIRZEPATIDE, SIDE EFFECTS, AFFORDABILITY. CANCER SIGNALS TIED TO GLP-1S - EARLY ONCOLOGY ANALYSES SUGGEST GLP-1 USE MAY CORRELATE WITH LOWER CANCER RISK OR SLOWER PROGRESSION, BUT RESEARCHERS STRESS IT’S NOT PROOF YET. KEYWORDS: ASCO, CANCER RISK, INFLAMMATION, CORRELATION, CLINICAL STUDIES. OPENAI’S CONFIDENTIAL IPO FILING - OPENAI CONFIDENTIALLY FILED FOR AN IPO WHILE EXPLORING A SHARE SALE FOR EMPLOYEES, SPOTLIGHTING THE COST AND HYPE OF THE AI BOOM. KEYWORDS: OPENAI IPO, CHATGPT, DATA CENTERS, PROFITABILITY, TENDER OFFER. NUCLEAR RISKS AFTER NEW START - SIPRI WARNS NUCLEAR WEAPONS ARE REGAINING PROMINENCE AS NEW START EXPIRES AND MODERNIZATION ACCELERATES, RAISING MISCALCULATION RISKS. KEYWORDS: SIPRI 2026, WARHEADS, HIGH ALERT, ARMS CONTROL, CHINA BUILDUP. IRAN–ISRAEL CEASEFIRE AND HORMUZ - PRESIDENT TRUMP SAID A BROADER IRAN–ISRAEL DEAL COULD COME WITHIN DAYS, BUT THE CEASEFIRE REMAINS FRAGILE WITH RISKS TO THE STRAIT OF HORMUZ. KEYWORDS: CEASEFIRE, RETALIATION, HEZBOLLAH, HORMUZ, OIL SHIPPING. CHINA’S EXPORT SURGE AND SURPLUS - CHINA’S EXPORTS JUMPED IN MAY AS BUYERS RUSHED ORDERS AMID GEOPOLITICAL UNCERTAINTY, THOUGH ECONOMISTS WARN THE BOOST MAY FADE. KEYWORDS: EXPORTS, IMPORTS, TRADE SURPLUS, DEMAND, OVERCAPACITY CRITICISM. NVIDIA AND SK HYNIX AI MEMORY PUSH - NVIDIA AND SK HYNIX STRUCK A LONG-TERM PARTNERSHIP FOCUSED ON NEXT-GENERATION MEMORY AND FASTER CHIP-MAKING, REFLECTING AI INFRASTRUCTURE BOTTLENECKS. KEYWORDS: AI FACTORIES, MEMORY SUPPLY, SEMICONDUCTOR, MANUFACTURING AUTOMATION, SCALE. GLIOBLASTOMA FIGHT AND NEW RESEARCH - AUSTRALIA MOURNS CANCER RESEARCHER RICHARD SCOLYER, AS SCIENTISTS PUSH COMBINATION APPROACHES AGAINST GLIOBLASTOMA’S STUBBORN RESISTANCE. KEYWORDS: GLIOBLASTOMA, IMMUNOTHERAPY, VACCINE, BLOOD-BRAIN BARRIER, PERSISTOR CELLS. Episode Transcript China’s brain implant milestone Let’s start with that brain-tech milestone. China has approved a brain-computer interface implant called NEO for commercial sale after it completed clinical trials. The device is aimed at helping people with paralysis and spinal cord injuries, and reports suggest it’s headed toward wider rollout through China’s state healthcare system. What makes this especially notable is the timing: Neuralink is still in limited human testing and hasn’t reached broad approval. China’s faster move could give it an early advantage in setting standards—while also bringing big unresolved questions into sharper focus, like surgical safety, how the body reacts over time, and how to protect intensely personal neural data from misuse or hacking. South Africa’s twice-yearly HIV prevention Staying on health, South Africa has begun rolling out lenacapavir—an injectable HIV-prevention medicine given just twice a year. President Cyril Ramaphosa called it a turning point, and for a country carrying the world’s highest HIV burden, it’s easy to see why. The key appeal is simple: many people struggle to take a daily pill consistently, and prevention only works when it’s actually used. Trials in South Africa and Uganda showed very high protection, including a headline-making Johannesburg study that reported complete protection over a six-month period. But the rollout also highlights a familiar challenge—access. South Africa has funding to cover hundreds of thousands of people for a year, with the first doses going to facilities in the hardest-hit provinces and prioritized for groups at higher risk. Advocates say that’s still nowhere near enough for real population-level impact, arguing that millions of doses a year would be needed. And reaching some groups may be harder now, after U.S. aid cuts closed specialized clinics that people trusted for privacy and stigma-free care. The government says staff training and service changes are underway, but the test will be whether people feel safe enough to show up. GLP-1 drugs: benefits and risks Now to the GLP-1 wave—drugs originally built for diabetes that have become mainstream weight-loss treatments. A new U.S. profile highlights just how broad the conversation has become: one patient says an off-label GLP-1 eased severe joint inflammation quickly, and later helped drive major weight loss. Doctors point to potential upsides beyond the scale—better mobility, better overall health, and possibly fewer obesity-related complications over time. But it’s not a miracle with no trade-offs. Many patients still report unpleasant stomach side effects, and there’s growing discussion about something harder to quantify: some people say they feel less joy or interest in things they used to enjoy—an effect that may improve if dosing changes. Meanwhile, access remains a huge dividing line. Even with public programs moving toward coverage, many privately insured patients still face steep costs, and clinicians are experimenting informally with strategies like spacing doses farther apart to maintain results—ideas that now need proper trials to confirm what’s safe and effective. Cancer signals tied to GLP-1s Related to that, oncology researchers are increasingly asking whether GLP-1 drugs might be connected to cancer outcomes—not as a proven treatment, but as a possible protective factor. New analyses presented at a major cancer meeting suggest GLP-1 use is linked, in medical-record studies, to lower risk in several cancers and to slower disease progression in some groups. One dataset study found an association with reduced risk across multiple cancers, with some of the strongest signals reported in areas like breast and colorectal cancer. Another analysis found women taking GLP-1s were less likely to develop breast cancer. Important caveat: these findings are correlational. Medical databases can miss crucial details—like lifestyle changes, other illnesses, or why a particular patient was prescribed a drug in the first place. Still, the pattern is intriguing enough that researchers are now launching studies to look for biological clues beyond weight loss, including changes in inflammation and metabolism. OpenAI’s confidential IPO filing In Australia, the death of Richard Scolyer—former Australian of the Year—has refocused attention on glioblastoma, one of the most aggressive brain cancers. Despite huge progress in many other cancers, glioblastoma outcomes have barely improved for decades. The reason is brutal biology and brutal geography. These tumors are hard to remove cleanly without damaging essential brain function, they often resist standard drugs, and they tend to return. Researchers have been exploring new approaches, including the kind of personalized immunotherapy and vaccine strategy Scolyer himself pursued, which reportedly helped delay recurrence. The broader takeaway is that progress is coming, but likely through combination therapies rather than one single breakthrough—and that real gains will take sustained investment in a disease that has long been a graveyard for easy answers. Nuclear risks after New START Turning to business and tech: OpenAI has confidentially filed paperwork for an initial public offering, keeping the door open to what could be one of the biggest Wall Street debuts in years. The company says it hasn’t decided when—or even whether—to go public, noting that staying private can make some strategic moves simpler. But the filing matters because it signals readiness, and it comes as investor appetite for AI exposure remains intense. OpenAI’s scale is enormous—ChatGPT is now estimated at roughly 900 million monthly users—yet profitability is still out of reach, largely because running and expanding AI systems requires massive data-center capacity and expensive computing. There’s also a secondary story here: OpenAI is reported to be considering a share sale that would let employees cash out some stock while the company weighs IPO timing—an event that could ripple through tech hubs via hiring, investment, and even housing markets. Iran–Israel ceasefire and Hormuz In the semiconductor world, NVIDIA and SK hynix announced a long-term partnership aimed at next-generation memory and faster chip development—one more sign that the AI boom is now constrained not just by ideas, but by components and supply. In plain terms, modern AI systems are hungry for fast memory and reliable production, and chipmakers are trying to shorten the time it takes to design and ramp manufacturing. The significance isn’t the brand names—it’s the direction: more automation in factories, more coordination across the supply chain, and an arms-race pace to support what companies increasingly call “AI factories.” China’s export surge and surplus Now to security and geopolitics. A major new SIPRI report warns that nuclear-armed states are again treating nuclear weapons as central tools of national power, reversing decades of efforts to reduce their role. SIPRI estimates the world still has over twelve thousand nuclear warheads, with thousands in military stockpiles and a significant number deployed and ready—especially in the U.S. and Russia. The real alarm bell is the trend line: modernization is accelerating across all nuclear-armed states, transparency is shrinking, and crisis-management channels are weaker. This warning lands right after the expiration of the New START treaty earlier this year, which had been one of the last major guardrails limiting U.S. and Russian strategic weapons. SIPRI also flags China’s rapid build-up and renewed European debate about nuclear arrangements—signals that the old arms-control era is giving way to a more uncertain, competitive one. NVIDIA and SK hynix AI memory push In the Middle East, President Donald Trump said a deal to end the Iran–Israel war could be reached within a matter of days, claiming both sides had agreed through him to halt strikes. He also suggested the agreement would include preventing Iran from obtaining nuclear weapons and reopening the Strait of Hormuz. But the immediate reality looks fragile. A ceasefire that’s been in place since April reportedly suffered a recent breakdown after strikes linked to Hezbollah in Beirut, followed by Iranian missile retaliation and then Israeli strikes inside Iran. Even when leaders signal restraint, the region’s interconnected fronts mean a single incident can spiral quickly. Why the Strait of Hormuz keeps coming up is straightforward: it’s a critical route for global oil shipping, and anything that threatens passage can quickly rattle energy markets and broader economic confidence. Glioblastoma fight and new research And finally, China’s economic pulse. New data show exports accelerated sharply in May, with import growth also strong and the trade surplus widening. Analysts say overseas buyers may have rushed orders early—trying to lock in supplies amid uncertainty tied to the Gulf conflict and possible price increases, while demand for AI-related hardware remained strong. Economists caution this may not last: other factory indicators suggest new export orders are already cooling, which could mean the surge was partly a timing effect. Still, it matters because exports remain a preferred engine for China’s growth at a time when domestic demand is uneven—and because a rising surplus adds fuel to international criticism over subsidies and industrial overcapacity. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Government stakes in AI firms & US military accelerates AI adoption - News (Jun 8, 2026)

Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad [https://try.elevenlabs.io/tad] - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily [https://try.prezi.com/automated_daily] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: GOVERNMENT STAKES IN AI FIRMS - A RARE POLITICAL CROSSOVER IS EMERGING AS DONALD TRUMP AND BERNIE SANDERS BOTH FLOAT IDEAS FOR THE PUBLIC TO SHARE IN AI PROFITS, INCLUDING TALK OF PUBLIC OWNERSHIP STAKES AND WEALTH FUNDS. KEYWORDS: PUBLIC STAKE, AI COMPANIES, JOBS, NATIONAL SECURITY, WEALTH FUND. US MILITARY ACCELERATES AI ADOPTION - A NEW US NATIONAL SECURITY PRESIDENTIAL MEMORANDUM ORDERS FASTER ADOPTION OF ADVANCED AI ACROSS DEFENSE AGENCIES, WITH NEW LIMITS AROUND CENSORSHIP AND UNLAWFUL DOMESTIC SURVEILLANCE. KEYWORDS: PENTAGON, AI MODELS, AUTONOMOUS WEAPONS, PROCUREMENT, GUARDRAILS. ISRAEL–IRAN STRIKES SHAKE MARKETS - ISRAEL LAUNCHED FRESH AIRSTRIKES ON IRAN, MET BY IRANIAN MISSILE FIRE, REVIVING REGIONAL ESCALATION FEARS AND PUSHING OIL HIGHER WHILE EQUITIES SLIPPED. KEYWORDS: AIRSTRIKES, BALLISTIC MISSILES, BRENT CRUDE, REGIONAL CONFLICT, MARKET VOLATILITY. NUCLEAR ARMS ROLLBACK CONCERNS - SIPRI’S YEARBOOK 2026 WARNS THE LONG DECLINE IN GLOBAL NUCLEAR WARHEADS MAY BE ENDING AS MODERNIZATION ACCELERATES, TRANSPARENCY FALLS, AND NEW START HAS EXPIRED. KEYWORDS: SIPRI, NUCLEAR MODERNIZATION, NEW START, HIGH ALERT, ARMS CONTROL. NEW WEEKLY DIABETES DRUG RESULTS - PHASE 3 DATA SUGGESTS THE EXPERIMENTAL WEEKLY INJECTION RETATRUTIDE SIGNIFICANTLY LOWERS HBA1C AND DRIVES NOTABLE WEIGHT LOSS IN ADULTS WITH TYPE 2 DIABETES, THOUGH LONGER-TERM COMPARISONS ARE STILL NEEDED. KEYWORDS: RETATRUTIDE, HBA1C, WEIGHT LOSS, TRIAL RESULTS, SIDE EFFECTS. TWICE-YEARLY HIV PREVENTION ROLLOUT - GAUTENG IS STARTING A ROLLOUT OF LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION INJECTION AIMED AT PEOPLE AT HIGH RISK, SUPPORTING SOUTH AFRICA’S 2030 GOALS. KEYWORDS: LENACAPAVIR, HIV PREVENTION, GAUTENG, LONG-ACTING INJECTION, PUBLIC HEALTH. UK PUSH FOR CHILD SAFETY CONTROLS - UK PRIME MINISTER KEIR STARMER IS PRESSURING TECH COMPANIES TO ADD DEVICE-LEVEL TOOLS TO CURB NUDE IMAGE SHARING BY CHILDREN, WITH LEGISLATION THREATENED IF FIRMS DON’T MOVE QUICKLY. KEYWORDS: CHILD SAFETY, DEVICE-LEVEL CONTROLS, SEXTORTION, AGE CHECKS, REGULATION. CHIP MEMORY SUPPLY FOR AI - NVIDIA AND SK HYNIX ARE TEAMING UP LONG-TERM TO SECURE NEXT-GENERATION MEMORY FOR AI SYSTEMS, REFLECTING HOW HARDWARE SUPPLY CONSTRAINTS ARE SHAPING THE PACE OF AI BUILDOUTS. KEYWORDS: AI INFRASTRUCTURE, MEMORY BOTTLENECK, SEMICONDUCTOR SUPPLY, PARTNERSHIP, CAPACITY. Episode Transcript Government stakes in AI firms Let’s start with artificial intelligence—because the conversation is shifting from “who builds it” to “who benefits from it.” In the US, officials and politicians are increasingly debating whether the public should hold an ownership stake in major AI companies. The argument is straightforward: if AI is going to reshape jobs, productivity, and national security, the upside shouldn’t flow only to private shareholders. OpenAI CEO Sam Altman has reportedly discussed the concept with Senator Bernie Sanders, whose camp has floated a major public stake to fund a public wealth fund—though support for the exact number is far from settled. What’s notable is that President Donald Trump has also talked about Americans becoming “partners” in the AI boom, and is expected to convene top AI leaders at the White House. Abroad, similar instincts are showing up in different forms—like Europe pushing to reduce dependence on US cloud giants for sensitive government work, and the UK setting up a sovereign AI investment fund. No deal is close. But the fact that “public ownership” is now part of the mainstream AI debate signals a turning point: governments are preparing to treat AI less like a typical tech sector—and more like critical infrastructure. US military accelerates AI adoption At the same time, the US is moving to speed AI adoption inside the military. President Trump has signed a National Security Presidential Memorandum directing defense agencies to accelerate the use of advanced AI across missions, and to pull in leading models from multiple vendors rather than relying on a single provider. There are also two political signals baked into the order. One: the Pentagon is being told to update its approach to autonomous weapon systems—an area that’s been debated for years, but is now being pushed toward clearer rules. Two: the memo includes boundaries meant to address public concerns, including language against building defense AI designed to censor speech, embed ideological bias, or enable unlawful surveillance of Americans. Another line stands out for industry: it bars companies from disabling or materially altering AI systems used by US warfighters without government approval. In plain English, once a system is in the field, Washington wants to ensure it can’t be remotely “switched off” by a vendor decision. Israel–Iran strikes shake markets Now to the Middle East, where a fragile pause has been shaken. Israel carried out new airstrikes on Iran—described as the first direct exchange since an April ceasefire that paused a US–Israel war with Iran. Iranian state media reported explosions in multiple cities, including Tehran and Isfahan. Iran then responded by firing around ten ballistic missiles toward northern Israel, after Israel also bombed a target in southern Beirut. President Trump publicly urged both sides to stop shooting, a comment that also highlights the tension between Washington’s stated posture and Israel’s on-the-ground decisions. The ripple effects were immediate across the region: Saudi Arabia reportedly sounded missile-alert sirens near an airbase that hosts US forces, and Israel said it worked to intercept a missile launched from Yemen, where the Houthis have been involved in the broader conflict. Markets reacted fast, too. Oil jumped, with Brent crude rising by several dollars to the mid‑90s per barrel range, and Asian stocks slid. The takeaway is familiar but important: even a limited exchange can quickly raise global economic anxiety, because energy prices and shipping risk can move on headlines alone. Nuclear arms rollback concerns Staying with security—one of the most sobering reads today comes from SIPRI’s Yearbook 2026. The Stockholm International Peace Research Institute warns that nuclear-armed states are increasingly treating nuclear weapons as instruments of national power again—reversing decades of efforts to reduce their role. SIPRI estimates the world had a little over twelve thousand nuclear warheads as of January 2026, with thousands in military stockpiles and roughly four thousand deployed. A significant share of deployed warheads remain on high operational alert, mostly in Russia and the United States. The big shift is trendline and trust. SIPRI expects the long-running decline in total warhead numbers to end, as dismantlement slows and new deployments accelerate. That warning lands as New START—the last major US–Russia nuclear arms control agreement—expired in February 2026. Add reduced transparency, weaker crisis-management channels, and rising geopolitical tension, and you get a higher risk of miscalculation. The report also points to China as the fastest-growing arsenal, while noting the US and Russia still hold the vast majority of stockpiled warheads—and both are modernizing under intense strategic competition. In Europe, SIPRI flags renewed debate about a bigger nuclear role in security planning, including interest in broader nuclear-sharing arrangements, alongside claims of Russian nuclear deployments in Belarus. And politically, the non-proliferation system looks shakier after the 2026 NPT Review Conference again failed to produce an outcome document—raising questions about how much cooperation remains in the tank. New weekly diabetes drug results On health news, there’s a potentially significant development for type 2 diabetes. Phase 3 trial results suggest an experimental weekly injection called retatrutide can both lower blood sugar and reduce body weight—two outcomes that are often linked, but not always easy to achieve together. In a forty-week study of adults not already on diabetes medication, average long-term blood sugar, measured by HbA1c, fell substantially more with retatrutide than with placebo. Participants also saw sizable average weight loss, alongside improvements in markers like cholesterol and blood pressure. Experts describe the results as encouraging—possibly life-changing for some patients—but there are important caveats. We still need longer-term data, and there wasn’t a direct head-to-head comparison here against some of today’s leading drugs. And like other medicines in this space, side effects were mainly gastrointestinal, with a small number of serious adverse events reported across the study groups. The story to watch next is how it performs over time, in real-world care, and against established options. Twice-yearly HIV prevention rollout Also in public health, South Africa is expanding prevention tools against HIV. Gauteng’s Department of Health says it will begin rolling out lenacapavir on Monday as a long-acting prevention injection. The key practical difference: it’s given only twice a year, aimed at HIV-negative people at high risk of infection. The first phase is planned across more than a hundred facilities, with tens of thousands of people expected to receive the injection by early next year. Officials say supplies will be delivered regularly to avoid interruptions. Why it’s interesting is not just the medicine, but the strategy: offering choices. Long-acting prevention can help people who struggle with daily pills, or who face barriers like stigma, unstable schedules, or limited clinic access. It’s part of a broader push toward ending AIDS as a public health threat by 2030—and it puts a spotlight on whether health systems can scale prevention in a way that’s consistent and equitable. UK push for child safety controls In the UK, the government is turning up the pressure on tech companies over child safety. Prime Minister Keir Starmer has given major firms three months to introduce device-level controls meant to stop children from sending or receiving nude images. If companies don’t comply, the government is warning it will legislate. The concept is a shift in responsibility: not just moderating content after it appears on a platform, but building safeguards into the devices themselves—so the camera and operating system can detect and block explicit imagery in the moment. Politics around the plan are already heated. Critics from across the spectrum argue the government is either moving too slowly or aiming at the wrong target, and ministers are also weighing an under‑16 social media ban while gathering evidence on screen-time guidance and device use in schools. The broader context is grim: online exploitation is evolving, including AI-generated child abuse material and sextortion schemes. The policy question is how far governments should go in mandating “safety by default,” and how to do it without creating new privacy or enforcement problems. Chip memory supply for AI Finally, in tech industry news with real-world consequences for AI’s pace: NVIDIA and SK hynix have announced a long-term partnership to co-develop next-generation memory aimed at large-scale AI systems. This matters because the bottlenecks in AI aren’t only about chips with flashy headlines—memory supply and performance can be the limiting factor for building and running powerful systems at scale. Securing reliable access, and shortening development timelines, can influence everything from data center expansion to the cost of deploying AI in business and government. The two companies also signaled they want to use AI-driven simulation and “digital twin” techniques to streamline chip development and manufacturing. Put simply: using sophisticated modeling to design faster, waste less, and get new hardware into production sooner. Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]

Base editing in human embryos & AI-designed universal coronavirus vaccine - News (Jun 7, 2026)

Please support this podcast by checking out our sponsors: - Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron [https://www.stock-mvp.com/?via=ron] - Prezi: Create AI presentations fast - https://try.prezi.com/automated_daily [https://try.prezi.com/automated_daily] - Effortless AI design for presentations, websites, and more with Gamma - https://try.gamma.app/tad [https://try.gamma.app/tad] Support The Automated Daily directly: Buy me a coffee: https://buymeacoffee.com/theautomateddaily [https://buymeacoffee.com/theautomateddaily] TODAY'S TOPICS: BASE EDITING IN HUMAN EMBRYOS - A COLUMBIA UNIVERSITY TEAM REPORTED BASE EDITING IN EARLY HUMAN EMBRYOS IN A BIORXIV PREPRINT, REVIVING SAFETY AND ETHICS DEBATES AFTER THE CRISPR-BABY SCANDAL. KEYWORDS: BASE EDITING, EMBRYOS, MOSAICISM, ETHICS, CRISPR. AI-DESIGNED UNIVERSAL CORONAVIRUS VACCINE - CAMBRIDGE RESEARCHERS SAY AN AI-DESIGNED “UNIVERSAL SARBECOVIRUS” VACCINE LOOKED SAFE IN A SMALL PHASE 1 TRIAL, AIMING FOR BROAD PROTECTION ACROSS SARS-LIKE VIRUSES. KEYWORDS: AI VACCINE DESIGN, SARBECOVIRUS, PHASE 1, VARIANTS, PREPAREDNESS. NEW WEIGHT-LOSS SHOT FOR DIABETES - PHASE 3 RESULTS SUGGEST RETATRUTIDE, A WEEKLY TRIPLE-ACTION INJECTION, LOWERED HBA1C AND WEIGHT IN TYPE 2 DIABETES, THOUGH LONGER-TERM COMPARISONS ARE STILL NEEDED. KEYWORDS: RETATRUTIDE, TYPE 2 DIABETES, HBA1C, WEIGHT LOSS, GLP-1. TWICE-YEARLY HIV PREVENTION INJECTION - SOUTH AFRICA’S GAUTENG PROVINCE IS ROLLING OUT LENACAPAVIR, A TWICE-YEARLY HIV PREVENTION SHOT, FOCUSING ON HIGH-RISK GROUPS TO SUPPORT THE 2030 AIDS GOALS. KEYWORDS: LENACAPAVIR, PREP, LONG-ACTING INJECTION, GAUTENG, HIV PREVENTION. ROBOTS VS REALITY IN CHINA - CHINA’S HUMANOID ROBOTS ARE GETTING FLASHIER AND DRAWING ORDERS, BUT ANALYSTS SAY REAL-WORLD USEFULNESS STILL LAGS AND COMMERCIALIZATION REMAINS LIMITED. KEYWORDS: HUMANOID ROBOTS, CHINA, ROBOTICS DEMAND, LOGISTICS, BUBBLE RISK. US MILITARY AI ACCELERATION MEMO - PRESIDENT TRUMP SIGNED A NATIONAL SECURITY MEMO PUSHING FASTER ADOPTION OF ADVANCED AI ACROSS US DEFENSE AGENCIES, INCLUDING NEW ATTENTION TO AUTONOMOUS WEAPONS POLICY. KEYWORDS: PENTAGON AI, NATIONAL SECURITY MEMORANDUM, AUTONOMOUS WEAPONS, VENDORS, GOVERNANCE. PUBLIC STAKE IDEA FOR AI FIRMS - THE WHITE HOUSE HAS DISCUSSED WAYS FOR THE PUBLIC TO SHARE IN AI-COMPANY GAINS, INCLUDING A REPORTED CONCEPT OF AN EQUITY STAKE IN OPENAI TIED TO A PUBLIC WEALTH FUND. KEYWORDS: OPENAI STAKE, PUBLIC WEALTH FUND, AI POLICY, GOVERNMENT OWNERSHIP, EQUITY. AUSTRALIA’S AI DATA-CENTER POWER CRUNCH - AUSTRALIA’S DATA-CENTER BOOM IS POWERING CONSTRUCTION GROWTH BUT RAISING CONCERNS ABOUT ELECTRICITY DEMAND, PRICE PRESSURE, AND HOW MUCH LONG-TERM VALUE STAYS ONSHORE. KEYWORDS: AUSTRALIA DATA CENTERS, AI BOOM, AEMO, POWER DEMAND, WHOLESALE PRICES. US-IRAN TALKS ON ENDING WAR - TRUMP SAYS THE US AND IRAN ARE CLOSE TO AN AGREEMENT TO END A THREE-MONTH CONFLICT, BUT URANIUM REMOVAL AND VERIFICATION DETAILS REMAIN THE CRUCIAL STICKING POINTS. KEYWORDS: US-IRAN DEAL, ENRICHED URANIUM, VERIFICATION, TROOPS, CEASEFIRE TALKS. NASA’S QUIET-SUPERSONIC X-59 MILESTONE - NASA’S X-59 ACHIEVED ITS FIRST SUPERSONIC FLIGHT, ADVANCING A PROGRAM DESIGNED TO REDUCE SONIC BOOMS AND POTENTIALLY REOPEN OVERLAND SUPERSONIC TRAVEL. KEYWORDS: NASA X-59, QUESST, SUPERSONIC, SONIC BOOM, REGULATIONS. Episode Transcript Base editing in human embryos We’ll start with the headline that’s raising eyebrows in both science and ethics circles. A research team led by Dieter Egli at Columbia University has posted a preprint describing what appears to be the first use of “base editing” in early-stage human embryos. Unlike older approaches that cut DNA, base editing aims for more precise, single-letter changes—on paper, a safer direction. But the results still show major hurdles: edits often appeared in some cells but not others, and at higher doses the process could even stop embryos from dividing. The bigger story here is what this unlocks—and what it tempts. Supporters see a path toward mimicking naturally protective mutations tied to lower heart-disease risk or reduced severity in blood disorders like sickle cell disease. Critics warn it could make “embryo improvement” feel more reachable than it should, especially given how widely IVF and genetic testing are already available. For now, the message from the data is clear: the science is advancing, but it’s far from clinic-ready. AI-designed universal coronavirus vaccine Staying with health—and shifting from controversy to preparedness—researchers at the University of Cambridge and their spin-out, DIOSynVax, say they’ve completed an early human trial of a vaccine antigen designed entirely with computer simulations and machine learning. In a small Phase 1 study of healthy volunteers, the team reports no significant side effects. The ambition is the striking part: instead of building a vaccine around one known virus, they designed an antigen meant to represent shared features across the broader “sarbecovirus” family—the group that includes SARS-CoV-1 and SARS-CoV-2. If later trials show strong protection, it could mean fewer frantic updates every time a new variant appears, and faster vaccine design when a new relative of COVID shows up. New weight-loss shot for diabetes Another medical update with major real-world stakes: Phase 3 trial results suggest the experimental weekly injection retatrutide helped adults with type 2 diabetes significantly lower blood sugar and lose substantial weight over 40 weeks. Participants who weren’t already on diabetes medication saw meaningfully larger drops in HbA1c than placebo, and also lost far more body weight, alongside improvements in cholesterol and blood pressure. Researchers describe retatrutide as a “triple-action” drug, aiming to tackle appetite, glucose control, and energy use at the same time. Side effects were mostly in the familiar category for this class of drugs—mainly gastrointestinal—and experts are encouraged, while also pointing out what’s still missing: longer-term data and direct comparisons with established treatments like semaglutide or tirzepatide. Twice-yearly HIV prevention injection From treatment to prevention: South Africa’s Gauteng Department of Health is beginning a rollout of lenacapavir as a long-acting HIV prevention injection. It’s given twice a year and is aimed at HIV-negative people at higher risk of infection. The plan is to start across more than a hundred health facilities in the province, with a goal of reaching tens of thousands of people over the coming months. Public health officials are prioritizing groups that have often been underserved by prevention tools—especially adolescent girls and young women, sex workers, and others who face elevated risk. The significance is straightforward: adherence has long been one of the biggest barriers for HIV prevention, and a twice-yearly option could make staying protected much more realistic for many people. Robots vs reality in China Now to technology and the economy—and a reality check on humanoid robots. In China, robot makers are showing off increasingly agile humanoids, with companies claiming thousands of orders from governments and businesses. But analysts and investors are warning that demand still isn’t matching the scale of manufacturing ambition. A lot of these machines look impressive in controlled demos, yet struggle with messy, unpredictable environments—the places where a “general-purpose helper” would actually have to work. The near-term opportunity appears more practical: industrial sites and logistics, like warehouses, power plants, and data centers, where tasks are more structured and where a robot’s limits can be managed. The broader race is also taking shape geopolitically: the US is widely seen as stronger on advanced AI systems, while China’s edge is hardware supply chains, data, and mass production. Chinese regulators, notably, have even warned about bubble dynamics—big expectations, but limited real commercialization so far. US military AI acceleration memo On the US policy front, President Trump has signed a National Security Presidential Memorandum pushing faster adoption of advanced AI across defense agencies. The memo calls for rapid onboarding of top AI models from multiple vendors and for adapting commercial and open-source tools for military missions. It also signals more formal attention to autonomous weapons policy, directing the Defense Department to update guidance on how those systems are governed. One notable clause says companies shouldn’t be able to disable or modify AI used by US warfighters without government approval—an attempt to prevent critical tools from being turned off in a crisis. The memo also includes language aiming to limit certain domestic risks, saying defense agencies shouldn’t create or release AI designed to censor free speech, embed ideological bias, or enable unlawful surveillance of Americans. The big picture: Washington is trying to move quickly on military AI while also drawing some red lines—though how those lines hold up in practice is the real test. Public stake idea for AI firms And there’s another AI-related idea circulating that could reshape how the public relates to the industry. Trump says he’s been talking with AI companies about arrangements that would let “the American people” benefit directly from AI’s success. Reporting suggests discussions have included the federal government taking an equity stake in OpenAI, potentially routing proceeds into a proposed “Public Wealth Fund.” Supporters frame it as the public getting a stake in a transformational technology. Critics see risks: deeper government-corporate entanglement, and the possibility that ownership becomes a backdoor route to bailouts or political influence. It’s also notable that a similar concept is appearing from the political left, with proposals for AI companies to pay a tax in shares. Regardless of ideology, the underlying question is the same: if AI creates enormous private value, should the public have a built-in claim on part of it? Australia’s AI data-center power crunch Australia offers a different angle on the AI boom: the infrastructure behind it. The country is seeing a surge in data-center investment, including a proposed multi-billion-dollar complex in Sydney’s outer west. In the near term, it’s a genuine economic boost—big construction activity, big capital flows. But analysts warn the longer-term gains may be thinner than they look. Much of the highest-value equipment is imported, data centers run with relatively small staffing footprints, and there are mounting concerns about electricity demand. Australia’s energy market operator forecasts data-center power use rising fast, and climate analysts warn that if new renewable generation and storage don’t keep pace, wholesale power prices could rise materially over the next decade. Add in longstanding debates about how much tax revenue big tech contributes locally, and the question becomes: who really profits, and who pays for the grid upgrades? US-Iran talks on ending war To geopolitics now, where President Trump says the US and Iran are “very close” to an agreement meant to end a three-month conflict. Trump claims Iran has accepted it will not possess nuclear weapons, and he says remaining gaps are now down to wording—specifically, language that would bar Iran not only from developing a nuclear weapon, but from acquiring one by any means. He also emphasized the handling of Iran’s highly enriched uranium stockpile, arguing it should be removed and destroyed, with the US prepared to help do that either on-site or elsewhere in cooperation with Iran. The significance here is the potential for a diplomatic off-ramp from a volatile conflict. But the durability of any deal will hinge on the hard parts: verification, monitoring, and exactly what happens to nuclear material. Those details are often where agreements either become enforceable—or unravel. NASA’s quiet-supersonic X-59 milestone Finally, a milestone in the sky: NASA’s experimental X-59 aircraft has completed its first supersonic flight, breaking the sound barrier on June 5 as part of the agency’s Quesst mission. The point isn’t just speed. It’s noise. Supersonic passenger travel over land has been heavily restricted for decades largely because of the disruptive sonic boom. The X-59 is designed to soften that boom into something closer to a quiet thump, collecting the data NASA hopes could one day support new rules for overland supersonic flight. Next comes a careful expansion of the flight envelope—pushing faster and higher—before NASA can start answering the big question: can supersonic travel return without rattling the ground below? Subscribe to edition specific feeds: - Space news * Apple Podcast English [https://apple.co/4cLLrdt] * Spotify English [https://spoti.fi/4jN8Dui] * RSS English [https://bit.ly/the_automated_daily_space] Spanish [https://theautomateddaily.com/space_es/feed.xml] French [https://theautomateddaily.com/space_fr/feed.xml] - Top news * Apple Podcast English [https://apple.co/3PTvdUF] Spanish [https://apple.co/3ECCMgk] French [https://apple.co/4hmcxbB] * Spotify English [https://spoti.fi/3ZYXAW2] Spanish [https://spoti.fi/414h4JD] French [https://spoti.fi/3Di0jDe] * RSS English [https://bit.ly/the_automated_daily_news] Spanish [https://bit.ly/the_automated_daily_news_es] French [https://bit.ly/the_automated_daily_news_fr] - Tech news * Apple Podcast English [https://apple.co/3RYWbg4] Spanish [https://apple.co/4i0WqRM] French [https://apple.co/4bEAXMm] * Spotify English [https://spoti.fi/3S089pG] Spanish [https://spoti.fi/3EE2Fwv] Spanish [https://spoti.fi/3DlObRE] * RSS English [https://bit.ly/the_automated_daily_tech] Spanish [https://bit.ly/the_automated_daily_tech_es] French [https://bit.ly/the_automated_daily_tech_fr] - Hacker news * Apple Podcast English [https://apple.co/48QWyzj] Spanish [https://apple.co/4ke9jtE] French [https://apple.co/41E1qFd] * Spotify English [https://spoti.fi/45zD1kf] Spanish [https://spoti.fi/4hF8h81] French [https://spoti.fi/3QY26Ak] * RSS English [https://bit.ly/the_automated_daily_hacker_news] Spanish [https://bit.ly/the_automated_daily_hacker_news_es] French [https://bit.ly/the_automated_daily_hacker_news_fr] - AI news * Apple Podcast English [https://apple.co/3M6Tg1o] Spanish [https://apple.co/4315L7Y] French [https://apple.co/3DkZbPb] * Spotify English [https://spoti.fi/3tzOfrz] Spanish [https://spoti.fi/416m40q] French [https://spoti.fi/41HuJGW] * RSS English [https://bit.ly/the_automated_daily_hackernews_ai] Spanish [https://bit.ly/the_automated_daily_hackernews_es_ai] French [https://bit.ly/the_automated_daily_hackernews_fr_ai] Visit our website at https://theautomateddaily.com/ [ https://theautomateddaily.com/] Send feedback to feedback@theautomateddaily.com Youtube [https://www.youtube.com/@TheAutomatedDaily] LinkedIn [https://www.linkedin.com/in/the-automated-daily/] X (Twitter) [https://x.com/automated_daily]